Amneal Pharmaceuticals, Inc. Class A AMRX 深 滬
已收盤 08-01 16:00:00 美东时间
7.83
+0.010
+0.13%
華盛通- 最 高7.84
- 今 開7.72
- 成交量 150.55万股
- 最 低 7.665
- 昨 收 7.82
- 總市值 24.51亿
- 52周最高 9.475
- 市盈率 靜 --
- 換手率 0.48%
- 52周最低 6.685
- 委 比 -62.70%
- 總股本 3.13亿
- 歷史最高 24.48
- 量 比 1.07
- 振 幅 2.24%
- 歷史最低 1.24
- 每 手 1
- 風險率 0.52%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Amneal Pharmaceuticals Secures $2.1 Billion in Loans
An announcement from Amneal Pharmaceuticals ( ($AMRX) ) is now available. On Au...
今天 04:49
Shares of several biotechnology stocks are trading higher amid Vinay Prasad's departure as director of the FDA's Center for Biologics Evaluation and Research.
Shares of several biotechnology stocks are trading higher amid Vinay Prasad's d...
07-31 02:12
Amneal Pharmaceuticals Board Restructuring Amidst Financial Growth
Amneal Pharmaceuticals ( ($AMRX) ) just unveiled an update. Amneal Pharmaceutic...
07-21 20:24
Amneal Pharma's Subsidiary Pursues $1.8B Term Loan Facility, Launches $750M Senior Secured Notes Offering
Amneal Pharmaceuticals, Inc. ("Amneal") (NASDAQ:AMRX) announced that its subsidiary, Amneal Pharmaceuticals LLC (the "Issuer"), is seeking to borrow $1.800 billion aggregate principal amount of new seven-year term B
07-21 19:45
Amneal Pharma Preliminary Q2 Net Revenue $720M - $730M, Up ~3% YoY; Adj. EBITDA $180M - $185M, Up ~13% YoY
– Results Reflect Continued Financial Strength and Deleveraging –BRIDGEWATER, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) ("Amneal" or the "Company") today announced certain
07-21 19:43
Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032
Amneal Pharmaceuticals subsidiary seeks $1.8 billion in seven-year term loans and offers $750 million in senior secured notes due 2032. Proceeds will refinance existing term loans, repay ABL facility amounts, and cover related costs. The notes are secured by same assets as the term loans, with first-priority lien on collateral (excluding ABL priority collateral). The offering is for qualified institutional buyers and non-U.S. persons. The transac...
07-21 11:39
Amneal to Report Second Quarter 2025 Results on August 5, 2025
Amneal Pharmaceuticals will release its second quarter 2025 financial results on August 5, 2025, before market open. A live audio webcast will be held at 8:30 a.m. ET, accessible via the company's Investor Relations website or by dialing 1 (833) 470-1428 with access code 627786. The company, headquartered in Bridgewater, NJ, specializes in developing, manufacturing, and distributing over 280 pharmaceuticals, with a focus on affordable medicines, ...
07-09 12:00
Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciences
Amneal Pharmaceuticals and Kashiv BioSciences reported positive results from a Phase 3 clinical trial for ADL-018, a biosimilar to XOLAIR (omalizumab), demonstrating equivalence in efficacy and safety compared to the reference product. ADL-018 is designed to treat chronic urticaria and other conditions. A BLA submission to the FDA is expected in Q4 2025, and Amneal holds exclusive U.S. commercialization rights. With U.S. sales of XOLAIR exceeding...
06-25 12:00
How are generic drugmakers reacting to Trump’s push for domestic production?
Leading generic drugmakers have mixed views on President Donald Trump’s repeated threats to impose tariffs on pharmaceutical goods in a bid to push global pharma majors to shift their manufacturing bu...
06-18 00:36
Amneal Pharma Announces FDA Approval For Prednisolone Acetate Ophthalmic Suspension; Product Launch Planned For Q3 2025
Key complex product approval in the Affordable Medicines segment this yearCommercial launch planned for third quarter of 2025BRIDGEWATER, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. ("Amneal" or
06-12 20:10
